SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 27.88 |
Enterprise Value ($M) | 26.70 |
Book Value ($M) | -3.00 |
Book Value / Share | -0.13 |
Price / Book | -9.29 |
NCAV ($M) | -3.00 |
NCAV / Share | -0.13 |
Price / NCAV | -9.29 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | n/a |
Return on Assets (ROA) | -2.24 |
Return on Equity (ROE) | -3.14 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.25 |
Current Ratio | 1.25 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 1.47 |
Assets | 1.47 |
Liabilities | 4.47 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -11.40 |
Net Income | -10.23 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -10.26 |
Cash from Investing | 2.03 |
Cash from Financing | 5.01 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
2,218 | 4,239 | 52.32 | |
3,750 | 739 | 507.44 | |
1,137 | 1,074 | 105.87 | |
1,920 | 7,297 | 26.31 | |
(click for more detail) |
Similar Companies | |
---|---|
RGLS – Regulus Therapeutics Inc. | RMTI – Rockwell Medical, Inc. |
RNAZ – TransCode Therapeutics, Inc. | RVPH – Reviva Pharmaceuticals Holdings, Inc. |
RZLT – Rezolute, Inc. |
Financial data and stock pages provided by
Fintel.io